ENVALITH
オリエンタルチエン工業株式会社 logo

ORIENTAL CHAIN MFG. CO., LTD.

6380・Standard Market・Machinery

Official website
オリエンタルチエン工業株式会社 logo
ORIENTAL CHAIN MFG. CO., LTD.6380

Business

Oriental Chain Industry Co., Ltd. is a specialized industrial chain manufacturer founded in 1947. Its core operation is the Chain Business (approximately 93% of net sales), which manufactures and sells Power Transmission Roller Chains, Conveyor Chains, and Sprockets. The company also operates a Metal Injection Molding Business that produces high-value-added metal parts using the metal powder injection molding method, a Real Estate Leasing Business that manages a rental building in Koto-ku, Tokyo, and Others business handling gold bullion and similar items. Headquartered with its main factory in Hakusan City, Ishikawa Prefecture, the company's primary customers include domestic and overseas manufacturers of industrial machinery, automobiles, and medical devices. The company has been expanding its business foundation, including making Terada Seiko a subsidiary in 2024 and concluding a four-party business alliance with Katayama Chain, RK Japan, and Kaga Kogyo in December 2025.

Business Model

In the Chain Business, the company secures product adoption through proposal-based sales of proprietary original products such as its unique highly corrosion-resistant chains, and maintains profitability by flexibly implementing price pass-through. In the Metal Injection Molding Business, the company utilizes rare technologies such as the hollow MIM manufacturing process to produce high value-added parts for medical and automotive applications on a made-to-order basis. The Real Estate Leasing Business generates stable cash flow through fixed rental income, forming a structure that complements the fluctuation risk of the manufacturing businesses.

Company Strengths

For over 75 years since its founding, the company has specialized in the manufacture of Power Transmission Roller Chains, accumulating quality and technical capabilities through JIS Display Permit Factory certification (1955) and ISO-9001 certification (2003). The 8th Medium-Term Management Plan sets a goal of establishing the world's No. 1 quality and supply system in the large chain field, with the company's long manufacturing track record serving as the foundation for its competitive advantage.

In the Metal Injection Molding Business, the company possesses the Hollow MIM manufacturing method, a rare technology within the industry, and continues to expand orders for medical parts used in high-performance treatment equipment. The operating margin of this business remained at a high level of 16.2% in FY2026 (ending March 2026), and production capacity has also been enhanced through a new factory completed in November 2024.

In December 2025, the company entered into a four-company business alliance with Katayama Chain, RK Japan, and Kaga Industry, agreeing on mutual product supply, mutual outsourced production, mutual technical exchange, and mutual use of logistics networks. Combined with the abolition of the Sprockets Division and the consolidation of sales offices, the company has built a system that simultaneously promotes fixed cost reduction and optimal allocation of management resources.

ENVALITH's Perspective

Operating profit for FY2026 (ending March 2026) fell sharply to ¥15 million (versus ¥142 million in the prior period). In the first half, the company posted an operating loss due to soaring raw material and labor costs and the impact of US trade policy (tariffs). The price pass-through implemented in September 2025 allowed the company to barely secure a profit for the full year, but this was compounded by one-time costs including structural reorganization expenses associated with the abolition of the Sprocket Business Division and consolidation of sales offices, goodwill amortization of ¥22 million (versus ¥2 million in the prior period), and share issuance costs of ¥24 million. The ordinary loss of ¥17 million indicates fragility in the company's financial structure, and careful assessment is needed regarding the feasibility of the recovery scenario toward the projected operating profit of ¥270 million for FY2027 (ending March 2027).

Profit attributable to owners of parent of ¥126 million (up 26.3% year-on-year) reflects dependence on a gain on sale of investment securities of ¥157 million (extraordinary income), and does not reflect the earning power of the core business. Given the underlying reality of an ordinary loss of ¥17 million, the FY2027 (ending March 2027) ordinary profit forecast of ¥151 million assumes that both the full-year penetration of price pass-through and the effects of structural reforms will materialize smoothly, and downside risk remains depending on trends in North American tariffs and raw material prices.

Cash flow from operating activities for FY2026 (ending March 2026) turned positive at ¥338 million (versus negative ¥7 million in the prior period), aided by improvements in working capital (a ¥102 million decrease in trade receivables and an ¥80 million decrease in inventories). Meanwhile, although the company repaid ¥390 million in long-term borrowings, the current portion of long-term borrowings due within one year remains high at ¥795 million, and the short-term repayment burden remains heavy. Capital reinforcement through the exercise of stock acquisition rights (¥294 million in proceeds) has contributed to financial stabilization, but the future pace of exercises and progress in debt repayment will be key to financial soundness.

Growth Strategy

Aiming to normalize profitability through synergies from the four-company business alliance and five priority initiatives ahead of the first year of the 8th Three-Year Medium-Term Management Plan

Price pass-through implemented from September 2025 is expected to contribute on a full-year basis in FY2027 (ending March 2026). A framework to largely cover cost increases has been established since the second half of FY2026 (ending March 2026), and this will be the primary driver of the projected operating profit of ¥270 million in FY2027 (ending March 2026).

Fixed cost reduction is being pursued through the elimination of unprofitable businesses and organizational streamlining. Implementation was completed within FY2026 (ending March 2026), and in FY2027 (ending March 2026), both the elimination of restructuring-related expenses and the effects of fixed cost reduction are expected to contribute to improved earnings.

The alliance aims to reduce procurement costs through operational rationalization, develop new products, and establish the world's No.1 quality and supply capability in large roller chains. It is positioned as a core initiative of the 8th Three-Year Medium-Term Management Plan, with FY2027 (ending March 2026) as its first year.

Leveraging the new plant completed in November 2024, the company continues to expand orders for medical parts and automotive parts. In FY2026 (ending March 2026), net sales reached ¥247 million (up 13.5% year on year) and operating profit reached ¥39 million (up 24.8% year on year), achieving higher sales and profit. The company will continue to improve profitability by increasing the proportion of high value-added medical parts.

Through the newly established subsidiary Oriental GB Co., Ltd., the company holds gold bullion and other assets as financial strategic assets, building a funding base to support the medium- to long-term growth of its core businesses. Combined with capital enhancement through the exercise of stock acquisition rights (proceeds of ¥294 million recorded within FY2026, ending March 2026), the equity ratio improved to 43.3%.

Last updated: July 19, 2026